HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond

Executive Summary

More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.

You may also be interested in...



FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US

FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.

Misbranding Grades Coming For Compliant VMS Labeling If Found Missing From Proposed MPL

Under Senate legislation proposing mandatory listing with FDA for all supplements sold in US, a product labeled in compliance with all other agency regulations would be deemed misbranded if not registered for  proposed list.

With Mandatory Product Listing, FDA Not Looking For Gate To Open Or Close On Supplements

Mandatory product listings would help FDA eliminate gap of missing NDI notifications it expects haven't been filed and other information about ingredients but not establish pre-market approval tool.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel